Mavacamten

CAS 1642288-47-8

Interested in hearing more about this API?

Mavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM). It received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans. Mavacamten was also approved by Health Canada in October 2022 and by EMA in July 2023 for the same indication.

 

About the API

Therapeutic category

Cardiovascular

Regulations
US DMF
Systematic Name

6-[[(1S)-1-phenylethyl]amino]-3-propan-2-yl-1H-pyrimidine-2,4-dione

Molecular Formula

C15H19N3O2C15H19N3O2

Disclaimers:

This material might be protected by exclusive rights such as patents and/or supplementary protection certificates or extensions in certain jurisdictions, and therefore might not be available for specific countries. TAPI will only be able to offer and supply this pharmaceutical ingredient in the countries and exclusively for uses that are exempt from infringement of such exclusive rights in accordance with applicable law. TAPI requires adequate confirmation of the exempt use upon ordering.

The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources. For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.

 

Contact us

Step 1 of

    First name*
    Last name*
    Business email*
    Company*
    Job title*
    Country*
    I'm interested in*
    Segment of interest*
    Tell us more about your project
    Select product*
    Formulation
    Project type*
    Target market
    Quantity
    Comments
    Disclaimer: This material might be protected by exclusive rights such as patents and/or supplementary protection certificates or extensions in certain jurisdictions, and therefore might not be available for specific countries. TAPI will only be able to offer and supply this pharmaceutical ingredient in the countries and exclusively for uses that are exempt from infringement of such exclusive rights in accordance with applicable law. TAPI requires adequate confirmation of the exempt use upon ordering.
    By clicking submit, you are agreeing to our Privacy Policy